The PALM trial was conducted in the Democratic Republic of Congo, where the current outbreak is ongoing. ZMapp served as the control arm of the trial. The investigators decided to stop the trial after reviewing interim mortality data from 499 patients, Regeneron said in a statement. The trial was first initiated last year with three treatment arms: mAb114, remdesivir and ZMapp.
"This trial is a remarkable advance in the decades-long struggle to respond to Ebola," Regeneron quoted leading investigator Dr. Sumathi Sivapalasingam as saying in the statement.
Meanwhile, the New York Times reported on Monday, citing Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, that the mortality rate in REGN-EB3 was 6%, compared to 24% in ZMapp, 11% in mAb114, and 33% in remdesivir.
Price: 297.48, Change: -7.41, Percent Change: -2.43
|Sector Update: Health Care Stocks Outperform But Sti...|
|Sector Update: More Erosion for Tech Stocks in Late ...|
|Denmark's Genmab Chairman Pettersson to Step Down in...|
|Market Chatter: Google Resists Demands From Attorney...|
|Update: Puma Biotechnology Drops After Decline in Fl...|